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Abstract Targeting mechanisms that result in increased
concentrations of kynurenic acid (KYNA) in the brain has
been considered as a therapeutic approach for the treatment
of epilepsy and certain neurodegenerative disorders.
Recently,KYNAhasbeenimplicatedintheeffectsproduced
by the high-fat and low-protein/carbohydrate ketogenic diet
(KD) in a report demonstrating an increased production of
KYNA in vitro by one of the ketone bodies, b-hydroxybu-
tyrate, elevated by the KD. To further explore this associa-
tion,brainconcentrationsofKYNAwerecomparedinyoung
(3 weeks old) and adult (8–10 weeks old) rats that were
chronically exposed to the KD and regular diet. Exposure to
the KD resulted in the anticipated elevations of b-
hydroxybutyrate with accompanying decreases in glucose
concentrations. In comparison to rats fed the regular diet,
KYNA concentrations were signiﬁcantly (p\0.05)
increased in the hippocampus (256 and 363% increase in
young and adult rats, respectively) and in the striatum (381
and 191% increase in young and adult rats, respectively) in
KD-fedrats.KD-inducedincreasesinKYNAconcentrations
in young versus adult rats in the hippocampus and striatum
were comparable (p[0.05). Exposure to the KD had no
effect on KYNA concentrations in the cortex of young and
adult rats (p[0.05). In summary, chronic exposure to the
KD resulted in several-fold increases in KYNA concentra-
tionsindiscretebrainstructuresintherats.Thus,therelevant
clinical question for further exploration is whether KD-
inducedincreasesinKYNAconcentrationscantranslateinto
clinically signiﬁcant improvements in neuropsychiatric
diseases associated with KYNA hypofunction.
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Abbreviations
AMPA 2-Amino-3-(5-methyl-3-oxo-1,2-oxazol-4-
yl)propanoic acid
KD Ketogenic diet
KYNA Kynurenic acid
NMDA N-Methyl-D-aspartate
Introduction
Kynurenic acid (KYNA) is a metabolite of tryptophan and
is formed by an irreversible transamination of its metabolic
intermediate, kynurenine, with the aid of kynurenine
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as well as in the brain (Zadori et al. 2009). Accumulated
evidence points to the speciﬁc pharmacological actions of
KYNA, inducible enzymatic control of its production, and
consequent roles in several neuropsychiatric disorders
(Erhardt et al. 2009; Vamos et al. 2009; Kincses et al.
2010).
For example, KYNA has been demonstrated to block the
N-methyl-D-aspartate (NMDA), 2-amino-3-(5-methyl-3-
oxo-1,2-oxazol-4-yl)propanoic acid (AMPA), kainate, and
a7-nicotinic acetylcholine receptors at nM to lM concen-
trations (Zadori et al. 2009). Furthermore, changes in
KYNA concentrations have been implicated as causative or
compensatory in epilepsy and several neurodegenerative
disorders such as Parkinson’s, Alzheimer’s, and Hunting-
ton’s diseases (Erhardt et al. 2009; Zadori et al. 2009;
Vamos et al. 2009; Kincses et al. 2010). Thus, targeting
mechanisms that result in increased concentrations of
endogenous KYNA have been considered as a therapeutic
approach for the treatment of epilepsy and certain neuro-
degenerative disorders.
These disorders might also beneﬁt from therapies such
as the high-fat and low-protein/carbohydrate ketogenic diet
(KD) that interfere with glucose and ketone metabolism
(Gasior et al. 2006; Freeman and Kossoff 2010). Recently,
two studies explicitly provided the in vitro evidence
implicating KYNA in the effects produced by the KD.
First, NMDA-induced reduction of KYNA production was
reversed by two ketone bodies, acetoacetate and b-
hydroxybutyrate, elevated during the exposure to the KD in
bovine retinal slices (Thaler et al. 2010). Second, b-
hydroxybutyrate increased the synthesis of KYNA in brain
cortical slices and primary glial cultures (Chmiel-Per-
zynska et al. 2011). However, one limitation of these in
vitro studies is that they do not model complex conse-
quences of chronic exposure to the KD, such as ketosis
caused by elevated concentrations of all three ketone
bodies (i.e., acetone, acetoacetate, and b-hydroxybutyrate),
accompanying carbohydrate deprivation with resultant
decreases in glucose concentrations, and various biological
effects taking place at the cellular and organ levels (Bough
et al. 2006; Hartman et al. 2007; Maalouf et al. 2009).
Thus, the aim of the present study was to explore the
association of KYNA and the KD in vivo by employing a
rat model of chronic exposure to the KD that has been
broadly used in KD-related research, owing to its transla-
tional validity (Stafstrom 1999; Bough et al. 2002; Hart-
man et al. 2007). Speciﬁcally, concentrations of KYNA
were measured in discrete brain regions of rats chronically
exposed to the KD and regular diet for comparison. KYNA
concentrations were further compared in young and adult
rats since responses to the KD have been reported to be age
dependent (Bough et al. 1999; Prins and Hovda 2009).
Based on the available in vitro reports, we predicted that
exposure to the KD would increase brain concentrations of
KYNA in vivo.
Material and methods
Animals and exposure to the KD
Female Brown Norway rats (Charles River, Wilmington,
MA) weighing 50–70 g (approximately, 3 weeks old and
considered as young) or 125–150 g (approximately,
8–10 weeks old and considered as adult) were used in the
present study. They were housed under a 12-h light–dark
cycle (with standard controlled humidity and temperature
values).
The rats were fed ad libitum with the KD (F3666,
AIN76A-modiﬁed high-fat paste, BioServ, Frenchtown,
NJ, USA) for 21 consecutive days. The KD was composed
of approximately 78.8% fat, 8.4% protein, 5% cellulose,
less than 5% water and less than 1% carbohydrate, and was
supplemented with necessary minerals and amino acids.
Control rats received standard rodent diet (3430 Kliba
Nafag, Switzerland). On the 21st day of exposure to the
KD (or the regular diet in the control rats), rats’ brains were
collected and immediately frozen in liquid nitrogen for
further KYNA concentration determination.
Brain concentrations of KYNA
KYNA concentrations were measured in the cortex, stria-
tum,andhippocampusbymeansofhigh-performanceliquid
chromatography (HPLC) with ﬂuorescence detection as
described elsewhere (Turski et al. 1988; Shibata 1988). In
brief, specimens were sonicated in 2 vol (w/v) of distilled
water, immersed in boiling water bath for 10 min, and cen-
trifugedfor10 minat20,000 rpm.Theresultingsupernatant
was then diluted (1:1) with 0.2 N HCl and applied to Dowex
50-W hydrogen form prewashed with 0.1 N HCl. Columns
were subsequently washed with 1 ml 0.1 N HCl and 1 ml
water. KYNA was eluted with 2 ml of water. The eluate was
subjected to HPLC and detected ﬂuorometrically as descri-
bed elsewhere (Shibata 1988). KYNA concentrations (in
pmol/g wet tissue weight) were expressed as group means
(± SEM; n = 4–6/each structure).
Plasma concentrations of glucose
and b-hydroxybutyrate
Plasma concentrations of glucose (mg/dL) and b-
hydroxybutyrate (mM) were measured in selected animals
to conﬁrm that ketosis with accompanying hypoglycemia
developed in rats maintained on the KD; control rats that
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(Hartman et al. 2008). Blood samples were collected by
making a small incision on the tail’s skin at the time cor-
responding to the tissue collection for the measurements of
KYNA concentrations. Immediately following sampling,
glucose and b-hydroxybutyrate concentrations were mea-
sured using a test strip system and reader (Precision Xtra
Advanced Diabetes Management System with Precision
Xtra blood ketone test strips and blood glucose test strips;
Abbott Diabetes Care Inc., Alameda, CA) as described
elsewhere (Hartman et al. 2008). Plasma concentrations of
glucose and b-hydroxybutyrate were expressed as group
means (± SEM; n = 4/group).
Statistical analysis
Statistical analysis was performed using unpaired Student’s
t-test (plasma concentrations of glucose and b-hydroxy-
butyrate) or two-way analysis of variance (ANOVA; brain
concentrations of KYNA). When appropriate, post hoc
analysis was performed using Tukey test. Differences were
considered statistically signiﬁcant at p\0.05.
Results
Effect of the KD on plasma glucose and
b-hydroxybutyrate concentrations in young and adult rats
Incomparisontotheyoungratsmaintainedonaregulardiet,
a 21-day exposure to the KD resulted in signiﬁcant changes
in plasma concentrations of glucose (decrease from
104.0 ± 8.7 to 49.0 ± 13.6 mg/dL, respectively; p =
0.014)andb-hydroxybutyrate(increasefrom0.68 ± 0.15to
5.53 ± 1.21 mM, respectively; p = 0.007). In comparison
to the adult rats maintained on the regular diet, a 21-day
exposure tothe KD resulted in signiﬁcant changes inplasma
concentrations of glucose (decrease from 124.5 ± 8.5 to
59.0 ± 10.4 mg/dL, respectively; p = 0.003) and b-
hydroxybutyrate (increase from 0.75 ± 0.03 to 4.40 ±
0.90 mM, respectively; p = 0.007). In young versus adult
rats, the magnitude of the decrease in plasma glucose con-
centrations was comparable (52.9% ± 13.09 and 52.6% ±
8.3, respectively; p = 0.985). In young versus adult rats, the
magnitude of the increase in plasma b-hydroxybutyrate
concentrations was comparable (818.5% ± 178.5 and
586.7% ± 120.1, respectively; p = 0.323).
Effect of the KD on brain concentrations of KYNA
in young and adult rats
Two-way ANOVA indicated statistically signiﬁcant treat-
ment effect (F3,47 = 17.319; p\0.001) after aggregated
data for brain concentrations of KYNA across different
structures passed normality (p = 0.090) and equal variance
(p = 0.643) tests. Post hoc analysis (Tukey test) in rats
maintained on the regular diet (Fig. 1) revealed that con-
centrations of KYNA in young and adult rats were com-
parable in the hippocampus (p = 1.0), cortex (p = 0.371),
and striatum (p = 0.615). Likewise, concentrations of
KYNA in young and adult rats fed with the KD for 21 days
were comparable in these structures (i.e., hippocampus,
p = 0.50; cortex, p = 0.937; and striatum, p = 0.221).
Regardless of the age, a 21-day exposure to the KD
resulted in signiﬁcant increases in KYNA concentrations in
the hippocampus (young rats: p = 0.009; adult rats:
p\0.001) and striatum (young rats: p\0.001; adult rats;
p = 0.012) in KD-fed rats in comparison to the control rats
fed a regular diet (Tukey test; Fig. 1). Speciﬁcally, expo-
sure to the KD resulted in a 256 and 363% increase in
concentrations of KYNA in the hippocampus of the young
and adult rats, respectively. Furthermore, exposure to the
KD resulted in a 381 and 191% increase in concentrations
of KYNA in the striatum of young and adult rats, respec-
tively. In contrast, concentrations of KYNA in the cortex
were not affected by exposure to the KD in comparison to
the age-matching young (p = 0.879) and adult (p = 0.416)
rats fed a regular diet (Fig. 1).
Discussion
The results of the present study provide the ﬁrst in vivo
evidence that chronic exposure to the KD increases con-
centrations of KYNA in discrete brain regions (i.e., the
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Fig. 1 Concentrations (mean ± SEM; n = 3–6/each structure) of
KYNA (pmol/g wet tissue) in the hippocampus, cortex, and striatum
in young and adult rats fed a regular diet (open bars) or the KD (solid
bars). Asterisks represent signiﬁcant difference in the KD versus
standard diet-fed rats at p\0.05 (*), p\0.01 (**), or p\0.001
(***); ns donates non-signiﬁcant difference (Tukey test following
signiﬁcant ANOVA)
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123hippocampus and striatum, but not cortex) in rats. This
ﬁnding proposes a potential mechanism involved in the
therapeutic effects of the KD, especially in neuropsychi-
atric disorders associated with KYNA hypofunction.
The methodology of chronic exposure to the KD used in
the present study resulted in the development of chronic
ketosis with corresponding hypoglycemia. These metabolic
changes were consistent with those reported when the KD
was studied for its anticonvulsant properties in animals
(Appleton and De Vivo 1973; Greene et al. 2001; Hartman
et al. 2008; Samala et al. 2011). Also, KYNA concentra-
tions in brain structures of animals when fed a regular diet
in the present study corresponded with previously pub-
lished data (Gramsbergen et al. 1992). In contrast to pre-
vious reports, however, there was no age-dependent
increase in brain KYNA concentrations in young versus
adult rats. This lack of difference was likely due to a small
difference in age in the groups used in the present study
(approximately, 5–7-week difference) in comparison to
earlier studies (approximately, 18–21 months difference)
that reported age-dependent increases in KYNA concen-
trations (Moroni et al. 1988; Gramsbergen et al. 1992).
In the present study, concentrations of KYNA in the KD-
exposed rats increased 1.9- and 3.8-fold in the striatum and
hippocampus in comparison to control rats, respectively;
concentrations of KYNA in the cortex did not changed sig-
niﬁcantly. This differential effect suggests that the KD
affects speciﬁc brain structures in a unique way rather than
producing a global state of KYNA elevation. Alternatively,
different brain regions may have different capacities and/or
sensitivities to respond to the KD with resultant increases in
KYNA concentrations. Of note, brain-speciﬁc changes in
KYNA concentrations due to differential sensitivities of
KATs to various modulators (e.g., metabolic substrates, pH,
pharmacologicalinhibitors,orconvulsivestimulations)have
beenpreviouslyreported(Moronietal.2005;Maciejaketal.
2009; Han et al. 2010; Szyndler et al. 2011).
The effects of external factors on KYNA concentrations
in vivo have rarely been reported. Thus, it is difﬁcult to
compare the magnitude of the KD-induced increases in
KYNA in the present study to responses produced by other
means. Administration of kainic acid at doses that pro-
duced convulsions resulted in 200–500% increases in
KYNA concentrations in the piriform cortex, amygdala,
and cerebellum in rats (Baran et al. 1995). An approxi-
mately 50% increase in KYNA production was reported
after incubation of rat cortical slices and primary glial
cultures with b-hydroxybutyrate (Chmiel-Perzynska et al.
2011). Under similar experimental conditions, increases in
KYNA production did not exceed 100% after incubations
with several approved antiepileptic drugs (Kocki et al.
2006). Likewise, a reduction of Na
? concentration resulted
in a 20–30% increase in KYNA production (Turski et al.
1989). Probably, the greatest increases in KYNA produc-
tion in vitro (approximately, 155–170%) were reported
during the incubation of neuronal and glial preparations
with ammonia (Saran et al. 2004; Wejksza et al. 2006).
Since excessive increases in KYNA concentration may
have detrimental behavioral effects on, for example, cog-
nition or ambulatory activity (Vecsei and Beal 1990; Potter
et al. 2010), it is important to note that the KD is generally
well tolerated by the animals and no gross behavioral
abnormalities have been reported. In contrast, exposure to
the KD has been reported to produce generally positive
effects on spontaneous or disease-altered behavioral out-
comes (e.g., Murphy et al. 2004; Ziegler et al. 2005; Mantis
et al. 2009; Ruskin et al. 2011). Thus, increases in KYNA
concentrations produced by the KD do not appear to reach
levels that would result in behavioral side effects.
The exact mechanism whereby an exposure to the KD
would result in increases in KYNA concentrations is not
known.Invitrostudiesdemonstratedanincreasedactivityof
KYNA-producing KATs in cultured glial cells incubated
with b-hydroxybutyrate; this effect, however, was not con-
ﬁrmed in cortical homogenates (Chmiel-Perzynska et al.
2011).NotethatKYNAconcentrationswerenotchangedby
theKDinthepresentstudy.Furthermore,KYNAproduction
was enhanced in vitro by the addition of substrates that
increase cellular metabolism (Hodgkins and Schwarcz
1998). Of note, exposure to the KD, among others, increases
cellular metabolism (Bough et al. 2006), thus providing a
potential mechanistic explanation of the KD-induced
increases in KYNA concentrations reported here.
In summary, chronic exposure to the KD in rats resulted
in several-fold increases in KYNA concentrations in dis-
crete brain structures. The magnitude of these increases was
generally greater than increases produced by any other
modulators (e.g., antiepileptic drugs) studied so far under
physiological conditions. Given the proposed role of KYNA
in the pathophysiology of several neuropsychiatric disor-
ders, further studies in this area are justiﬁed. Also, the
development of small molecule-based approaches targeting
the kynurenine pathway to increase KYNA (e.g., via the
inhibition of kynurenine hydroxylase or kynureninase)
remains at the stage of pre-clinical testing. Thus, the KD
may offer an alternative and expedited way of obtaining the
clinical proof-of-concept evidence to test whether exoge-
nously induced increases in KYNA concentrations in the
brain can translate into clinically signiﬁcant improvements
in neuropsychiatric diseases associated with KYNA hypo-
function. Testing of this hypothesis is supported mecha-
nistically, since an increased cellular energy metabolism
has been implicated in the effects produced by the KD and
as a factor enhancing KYNA production. Further support
comes from a long history of clinical beneﬁt of the KD in
drug-resistant epilepsy syndromes and the proposed clinical
682 T. _ Zarnowski et al.
123utility of the KD in other neuropsychiatric disorders (Gasior
et al. 2006; Freeman and Kossoff 2010).
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